Molecular and cellular dynamics of measurable residual disease progression in myelodysplastic syndromes

Insights

Cancer relapse stems from measurable residual disease (MRD). This study reveals MRD

Area of Science:

  • Hematology
  • Oncology
  • Genomics

Background:

  • Cancer relapse originates from persistent measurable residual disease (MRD).
  • Molecular drivers of MRD progression remain largely unknown.
  • Myelodysplastic syndromes (MDS) relapse after stem cell transplantation (SCT) requires understanding MRD.

Purpose of the Study:

  • To identify unique features and molecular pathways of MRD.
  • To understand the evolutionary dynamics of MRD progression.
  • To discover novel therapeutic targets for MRD.

Main Methods:

  • Longitudinal single-cell multi-omic profiling (DNA, RNA, protein) of patient cohort.
  • Analysis of relapsed myelodysplastic syndromes (MDS) after stem cell transplantation (SCT).
  • Comparative genotype, phenotype, and immune response analysis.

Main Results:

  • Comprehensive molecular portrait of MRD cells with novel, shared markers.
  • MRD progression is an evolutionary process involving subclonal sweeps and cell state transitions.
  • Malignant cells adapt to T cells by rewiring IFN-γ responses for immune evasion.

Conclusions:

  • Longitudinal single-cell multi-omics is powerful for MRD identification and tracking.
  • Understanding MRD evolution reveals key immunoevasive pathways.
  • New avenues to target MRD persistence and progression are identified.